EP3075853B1 - Verfahren zur gewinnung von informationen über brustkrebs und kit zum nachweis von brustkrebs - Google Patents

Verfahren zur gewinnung von informationen über brustkrebs und kit zum nachweis von brustkrebs Download PDF

Info

Publication number
EP3075853B1
EP3075853B1 EP16163068.6A EP16163068A EP3075853B1 EP 3075853 B1 EP3075853 B1 EP 3075853B1 EP 16163068 A EP16163068 A EP 16163068A EP 3075853 B1 EP3075853 B1 EP 3075853B1
Authority
EP
European Patent Office
Prior art keywords
dna
breast cancer
methylation
methylated
biological sample
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
EP16163068.6A
Other languages
English (en)
French (fr)
Other versions
EP3075853A1 (de
Inventor
Kaya Tai
Genta NAGAE
Hiroyuki Aburatani
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Sysmex Corp
University of Tokyo NUC
Original Assignee
Sysmex Corp
University of Tokyo NUC
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Sysmex Corp, University of Tokyo NUC filed Critical Sysmex Corp
Publication of EP3075853A1 publication Critical patent/EP3075853A1/de
Application granted granted Critical
Publication of EP3075853B1 publication Critical patent/EP3075853B1/de
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
    • C12Q1/6886—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material for cancer
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/154—Methylation markers

Definitions

  • the present invention relates to a method of obtaining information on breast cancer in a subject and a kit for detecting breast cancer.
  • Breast cancer is a malignant tumor that occurs in the mammary duct or gland. Breast cancer is known as the leading cause of death from cancer in women.
  • clinical breast examination for detection of any lump in the breast and mammography, i.e., X-ray photography of the breast are performed.
  • an imaging method e.g., ultrasonography
  • fine-needle aspiration cytology are performed.
  • these examinations may result in discomfort or pain in the subject.
  • tumor markers such as carcinoembryonic antigen (CEA) and CA 15-3 are also performed.
  • CAA carcinoembryonic antigen
  • CA 15-3 CA 15-3
  • the tumor markers include markers used for cancers of different types from breast cancer.
  • the methods include, for example, a method based on information on methylation of DNA.
  • CpG sites (5'-(CG)-3') in base sequences of certain genes are used as markers.
  • information such as the presence or absence of cancer cells is obtained based on the analysis results of the methylation status of the markers.
  • Information is used as an index for diagnosis of cancer. For example, Dulaimi E. et al.,Tumor Suppressor Gene Promoter Hypermethylation in Serum of Breast Cancer Patients, Clin Cancer Res, vol. 10, p.
  • 6189-6193 discloses that the promoters of RASSF1A, APC, and DAP-kinase genes are highly methylated in the serum of patients with breast cancer and the methylation analyses indicate the usefulness of the markers in screening for breast cancer.
  • US 2011/318738 describes RIIAD1 (c1orf230) as one of differentially methylated genes in adenoma.
  • EP 2 341 150 describes methylation markers for breast cancer.
  • the number of genes used as markers for detecting breast cancer is few.
  • the present inventors have identified that, among the markers disclosed in Dulaimi E. et al.,Tumor Suppressor Gene Promoter Hypermethylation in Serum of Breast Cancer Patients, Clin Cancer Res, vol. 10, p. 6189-6193 (2004 ), the markers of RASSF1A and APC genes are highly methylated not only in breast cancer tissues but also various other cancer tissues.
  • the markers of RASSF1A and APC genes are highly methylated not only in breast cancer tissues but also various other cancer tissues.
  • a method for obtaining information for breast cancer in a subject comprises steps of: analyzing methylation status of a CpG site located in a promoter region of RIIAD1 gene in a DNA sample prepared from a biological sample of said subject; and obtaining information indicating the presence of breast cancer cells in the biological sample when the result in the determining step indicates the presence of a methylated CpG site.
  • the methylation status of SEQ ID NO: 7 is analyzed in the analyzing step.
  • the analyzing step is conducted by at least one method selected from the group consisting of mass spectrometry and methylation-specific PCR method.
  • the biological sample is a tissue, blood or serum.
  • the analyzing step comprises: calculating methylation frequency of the promoter region
  • the obtaining step comprises: comparing the frequency with a predetermined threshold; and obtaining information indicating the presence of breast cancer cells in the biological sample when the frequency is equal to or higher than the threshold.
  • the method comprises preparing a DNA sample from the biological sample.
  • the preparing step comprises treating DNA in the biological sample with bisulfite.
  • a reagent kit for detecting breast cancer comprising a primer that hybridizes to a promotor region of RIIAD1 gene, said promoter region comprising: a uracil base converted from unmethylated cytosine base by a bisulfite treatment; and methylated cytosine base, wherein the primer is used for analyzing methylation status of a CpG site in the promoter region of RIIAD1 gene in a DNA sample.
  • the primer is a primer comprising a base sequence SEQ ID NO: 3 or 4.
  • information is obtained from a DNA sample prepared from a biological sample collected from a subject.
  • the method also comprises the step of preparing a DNA sample from a biological sample obtained from a subject.
  • the biological sample is not particularly limited as long as it is a biological sample containing DNA of a subject.
  • the biological sample is preferably a sample containing a genomic DNA such as a clinical specimen.
  • the clinical specimen include body fluid, urine, cells obtained by fine-needle aspiration, and tissues obtained by operations or biopsies.
  • the body fluid include blood, serum, plasma, lymph fluid, ascitic fluid, bone marrow fluid, and nipple discharge.
  • the biological sample may also be a culture obtained by culturing cells or tissues collected from a subject.
  • the biological sample may be a formalin-fixed paraffin-embedded (FFPE) tissue sample collected from a subject.
  • FFPE formalin-fixed paraffin-embedded
  • the DNA sample can be prepared by extracting DNA from the biological sample.
  • a method for extracting DNA from a biological sample is well-known in the art.
  • DNA can be extracted by, for example, mixing the biological sample with a treatment solution containing a surfactant for solubilization of cells or tissues (such as sodium cholate and sodium dodecyl sulfate) and subjecting the resulting mixture to physical procedure (such as stirring, homogenization, and ultrasonication) to release DNA contained in the biological sample into the mixture.
  • a supernatant containing DNA released by centrifuging the mixture to precipitate cell debris is preferably used in a later-described analyzing step.
  • the obtained supernatant may be purified by any well-known method in the art.
  • DNA can also be extracted from the biological sample and purified by using a commercially-available kit.
  • the above-described preparing step further includes a step of fragmenting the extracted DNA.
  • methylated DNA immunoprecipitation (MeDIP) and non-methylated cytosine converting treatment as described below can be effectively performed.
  • Fragmentation of DNA may be performed by ultrasonication, alkaline treatment, restriction enzyme treatment, or the like.
  • alkaline treatment for example, a sodium hydroxide solution is added to a DNA solution to obtain a final concentration of 0.1 to 1.0 N and the mixture is incubated at 10 to 40°C for 5 to 15 minutes to fragment the DNA.
  • the restriction enzyme is appropriately selected based on the base sequence of DNA, which may be MseI or BamHI, for example.
  • the methods of the present invention involve determining the presence or absence of methylation of a CpG site located in a promotor region of RIIAD1 gene included in the DNA obtained from the biological sample.
  • CpG site used herein means a site of a sequence in which cytosine (C) and guanine (G) are adjacent in this order from 5' to 3' in the base sequence.
  • p in “CpG” represents a phosphodiester bond between cytosine and guanine.
  • the base sequence of the promoter region of RIIAD1 gene itself is well-known in the art.
  • the base sequence can be obtained from a well-known database provided by, for example, the National Center for Biotechnology Information (NCBI) (http://www.ncbi.nlm.nih.gov/) of the National Library of Medicine.
  • NCBI National Center for Biotechnology Information
  • the ID number of RIIAD1 gene is shown in Table 1.
  • the base sequence of the promotor region of the RIIAD1 gene is represented by SEQ ID NO: 1 (chr1: 151692000-151696132). [Table 1] Gene symbol Unigene ID Entrez Gene ID SEQ ID NO: RIIAD1 HS.297967 284485 1
  • the presence or absence of methylation of a CpG site can be analyzed based on the analysis result on methylation status in the promotor region.
  • the methylation analysis can be performed by analyzing the presence or absence of methylation of cytosine located in at least one CpG site among CpG sites located in a promoter region of RIIAD1 gene. In this case, only one CpG site may be analyzed, but a plurality of CpG sites is preferably analyzed for the presence or absence of methylation.
  • methylation analysis may be performed by analyzing methylation frequency in a promoter region of RIIAD1 gene.
  • methylation frequency means a ratio of the number of methylated CpG sites relative to the number of CpG sites located in the promoter region.
  • a target for analysis may be the entire promoter region or a part of the promoter region including at least one CpG site.
  • the target for analysis may contain only one CpG site, but the target for analysis preferably contains a plurality of CpG sites.
  • the position and number of CpG sites located in the promoter region of RIIAD1 gene are already known, and thus, in the embodiment, the number of methylated CpG sites itself in the promoter region can be used as the methylation frequency.
  • the methylation frequency may be a "methylation score" obtained by analyzing methylation status of a CpG site in DNA with mass spectrometry such as MassARRAY (registered trademark) as described below.
  • MassARRAY registered trademark
  • MassARRAY allows calculation of a methylation score based on a ratio between the area of a peak derived from methylated DNA fragment and the area of a peak derived from non-methylated DNA fragment obtained through measurement of DNA fragments.
  • the methylation frequency in a promotor region of RIIAD1 gene may be calculated by a hand method or a machine such as a computer.
  • the target for analysis is not particularly limited, and may be any CpG sites (or certain regions including the CpG sites) in the promoter region of RIIAD1 gene.
  • the target for analysis may be appropriately selected by a person skilled in the art.
  • the positions and number of CpG sites located in the promoter region of the gene are already known.
  • the target CpG sites or regions may be selected by routine experiments according to the well-known analysis method described below.
  • the analysis method to be used in the methods envisaged herein is not particularly limited.
  • the analysis method preferably includes a step of differentiating methylated DNA from non-methylated DNA, a step of amplifying DNA, and a step of detecting methylated DNA and/or non-methylated DNA.
  • the step of differentiating methylated DNA from non-methylated DNA may include a step of performing methylation sensitive restriction enzyme treatment, a MeDIP method, non-methylated cytosine converting treatment, or the like.
  • the step of amplifying DNA may include a step of performing PCR, quantitative PCR, IVT (in vitro transcription) amplification, SPIA (trademark) amplification methods, or the like.
  • the step of detecting methylated DNA and/or non-methylated DNA may include a step of performing electrophoresis, sequence analysis, microarray analysis, mass spectrometry, Southern hybridization, or the like.
  • the MeDIP method is used to enrich methylated DNA in a biological sample by immunoprecipitation using an anti-methylated cytosine antibody or an anti-methylated cytidine antibody, or an antibody which specifically recognizes a methylated DNA-binding protein.
  • methylation analysis may be performed by enriching methylated DNA in DNA obtained in the extracting step by the MeDIP method and analyzing methylation status of the obtained methylated DNA.
  • the methylated DNA enriched by the MeDIP method may be amplified by, for example, IVT amplification, and the methylation status of the obtained amplified product may be analyzed by using a microarray. This analysis method is referred to as "MeDIP on chip.”
  • the non-methylated cytosine converting treatment is used to react DNA extracted from a biological sample with a non-methylated cytosine conversion agent so as to convert non-methylated cytosine in the DNA to another base (uracil, thymine, adenine or guanine).
  • the non-methylated cytosine conversion agent is a substance that can react with DNA and convert non-methylated cytosine in the DNA to another base (uracil, thymine, adenine or guanine).
  • the non-methylated cytosine conversion agent to be preferably used is bisulfite such as sodium, potassium, calcium or magnesium bisulfite.
  • non-methylated cytosine in the DNA is converted to uracil due to deamination reaction, while methylated cytosine does not undergo such a base conversion.
  • the difference in methylation status of a CpG site in DNA is converted to the difference in a base sequence (C and U) by the non-methylated cytosine converting treatment using bisulfite.
  • the non-methylated cytosine converting treatment using bisulfite is referred to as "bisulfite treatment.”
  • the additive amount (concentration) of bisulfite is not specifically limited as long as it can sufficiently convert non-methylated cytosine in DNA.
  • the final concentration in a solution containing DNA is higher than or equal to 1 M, preferably 1 M to 15 M, and more preferably 3 M to 10 M.
  • the incubation condition (temperature and time) after addition of bisulfite may be appropriately selected depending on the additive amount of bisulfite. For example, when bisulfite is added at a final concentration of 6 M, the incubation is carried out at 50 to 80°C for 10 to 90 minutes.
  • Methylation status of CpG sites in DNA can be analyzed by analyzing the sequence of DNA after bisulfite treatment and detecting the difference in base sequence from the original sequence. This method is referred to as "bisulfite sequencing.”
  • the methylation status of CpG sites can be analyzed by mass spectrometry. Specifically, DNA after bisulfite treatment as a template is amplified by PCR using a primer set specific for a base sequence which is a target for analysis, and the obtained PCR product is subjected to IVT amplification to convert methylated cytosine and uracil respectively to guanine (G) and adenine (A).
  • the obtained IVT amplification product is cleaved with RNase A, and the difference in mass (16 Da) due to difference between G and A in the obtained nucleic acid fragments is detected using a MALDI-TOF (matrix assisted laser desorption/ionization time-of-flight) mass spectrometer to analyze methylation status of the DNA.
  • MALDI-TOF matrix assisted laser desorption/ionization time-of-flight
  • the site of IVT product cleaved with RNase A is between an arbitrary base sequence and the adjacent uracil (U) or thymine (T).
  • the base sequence and mass of the IVT product cleaved with RNase A can be predicted based on the base sequence of the template DNA. Accordingly, it is possible to identify a portion of the base sequence of the template DNA from which each peak obtained in MassARRAY (registered trademark) is originated. For example, when one CpG site is methylated in a DNA fragment, a peak obtained in MassARRAY (registered trademark) shifts to the side with an increased mass for 16 Da.
  • a shift of 32 Da is shown when two CpG sites in the DNA fragment are methylated, and a shift of 48 Da is shown when three methylated CpG sites in the DNA fragment are methylated.
  • the methylation status of CpG sites can be analyzed by a methylation-specific PCR (MSP) method.
  • MSP method is a method of analyzing the presence or absence of methylation of CpG sites by amplifying DNA after bisulfite treatment by PCR using a primer set described below and determining the presence or absence of a PCR product.
  • the MSP method utilizes a primer set that can amplify a base sequence where a CpG site to be analyzed is methylated (i.e. cytosine is not converted to uracil), but cannot amplify a base sequence where a CpG site is not methylated (i.e. cytosine is converted to uracil).
  • the presence of a PCR product indicates the methylation of the CpG site to be analyzed.
  • the MSP method may also utilize a primer set that cannot amplify a base sequence where cytosine in a CpG site to be analyzed is not converted to uracil, but can amplify a base sequence where cytosine in a CpG site is converted to uracil. In this case, the absence of a PCR product indicates the methylation of the CpG site to be analyzed.
  • the presence or absence of a PCR product can be verified by gel electrophoresis, for example.
  • the reaction solution after amplification is subjected to gel electrophoresis, and then the presence or absence of a PCR product band in the gel may be visually confirmed.
  • an image of the gel after electrophoresis is obtained, and then the resulting image may be analyzed by image analysis.
  • the image analysis can be performed, for example, by obtaining the gray value (e.g., band intensity) of pixels in the region where the PCR product is assumed to be present in the gel image and comparing the value to a predetermined threshold. Specifically, when the gray value is higher than or equal to the predetermined threshold, the result indicates the presence of a PCR product.
  • the predetermined threshold for the shading of the pixels is not particularly limited, and may be for example, a value indicating the gray value in pixels in the background or a value double or triple the above value.
  • Each primer in the primer set used for the MSP method may be appropriately designed by a person skilled in the art based on the base sequence including a CpG site to be analyzed.
  • Each primer is preferably designed so as to contain cytosine of the CpG site to be analyzed at the 3' end of the primer or in the vicinity thereof.
  • the methylation status of CpG sites may alternatively be analyzed with a microarray.
  • the microarray for analysis may be prepared by immobilizing a nucleic probe complementary to the base sequence of a promoter region of RIIAD1 gene on a substrate.
  • the microarray can be prepared according to a well-known method in the art.
  • DNA extracted from a biological sample is preferably labeled with a labeling substance well-known in the art.
  • the determination method of the methods envisaged herein preferably further includes a step of labeling the extracted DNA.
  • the labeling step is advantageously carried out after the DNA amplifying step because all DNA in the biological sample can be labeled.
  • the labeling substance include fluorescent substances, haptens such as biotin, and radioactive substances.
  • the fluorescent substances include Cy 3 , Cy 5 , FITC, and Alexa Fluor (trademark). Labeling of DNA facilitates measurement of a signal from a probe on the microarray.
  • the method for labeling DNA with the labeling substance is well-known in the art.
  • the above signal may be any suitable signal depending on the type of microarrays.
  • the signal may be an electric signal generated when a DNA fragment hybridizes to each probe on the microarray or a fluorescence or luminescence signal generated from a labeling substance when DNA to be analyzed is labeled as described above.
  • the signal can be detected using a scanner included in a normal microarray analyzer. Examples of the scanner include GeneChip (registered trademark) Scanner3000 7G (Affymetrix, Inc.), and Illumina (registered trademark) BeadArray Reader (Illumina, Inc.).
  • the presence of methylated CpG sites in the promotor region of RIIAD1 gene can be determined.
  • the methylation frequency obtained in the methylation analysis is more than or equal to a predetermined threshold
  • the presence of methylated CpG sites in the promotor region of RIIAD1 gene can be determined.
  • the predetermined threshold is not particularly limited. The predetermined threshold may be empirically set based on accumulated data on various biological samples. The threshold may be alternatively set as follows.
  • methylation frequency is analyzed for DNA extracted from a biological sample which is confirmed to be devoid of cancer cells derived from breast cancer (normal breast tissues or normal breast cells) and a biological sample containing a cancer cell derived from breast cancer.
  • a threshold is set within a range that is higher than the methylation frequency of the biological sample devoid of cancer cells and lower than the methylation frequency of the biological sample containing the cancer cell.
  • the threshold is set as a value that can highly accurately differentiate between the biological sample devoid of cancer cells and the biological sample containing the cancer cell.
  • information on breast cancer in a subject is obtained based on the analysis result obtained in the determining step.
  • Obtaining information on gynecologic cancer in a subject can refer to the prediction, diagnosis, or prognosis of breast cancer in said subject.
  • the information on breast cancer includes the presence or absence of cancer cells derived from breast cancer in a biological sample collected from a subject.
  • the information on breast cancer may include information used as an index for diagnosis of breast cancer or information supporting diagnosis of breast cancer.
  • the information includes information indicating the occurrence of breast cancer, indicating that the status of breast cancer or information indicating both of them in a subject.
  • the information includes, for example, the possibility of occurrence of breast cancer in a subject, or the risk for future occurrence of breast cancer in a subject.
  • the information on breast cancer in a subject who has already been affected by breast cancer may include prognosis of the subject, or a degree of progression (stage).
  • the result in the determining step indicates the presence of methylated CpG sites
  • information indicating the presence of cancer cells derived from breast cancer in a biological sample is obtained.
  • information indicating the occurrence of breast cancer or indicating that the status of breast cancer is poor (or aggravated) can be obtained.
  • Information indicating that a subject has a high risk for being affected by breast cancer or that a subject has already been affected by breast cancer can be obtained.
  • the information may indicate that prognosis of the subject is poor (or aggravated) or that the cancer is in a progressed stage.
  • the result in the determining step indicates the absence of methylated CpG sites
  • information indicating that a biological sample does not contain a cancer cell derived from breast cancer is obtained.
  • information suggesting no occurrence of breast cancer or information indicating that breast cancer is in a preferable status can be obtained.
  • the information may alternatively indicate that a subject has a low risk for becoming breast cancer or that a subject has not been affected by breast cancer.
  • the information may be indicative of a preferable prognosis of the subject or indicates that the cancer is in a relatively early stage.
  • the present disclosure also encompasses a marker for obtaining information on breast cancer by methylation analysis (hereinafter, simply referred to as "marker").
  • the marker envisaged herein is a nucleic acid which is isolated from the subject and includes at least one selected from CpG sites located in a promotor region of RIIAD1 gene.
  • the methylation status of the marker is analyzed, and information on breast cancer in a subject can be obtained based on the analysis result.
  • nucleic acid derived from a nucleic acid isolated from a subject used as a marker for obtaining information on breast cancer has a sequence obtained by subjecting a contiguous base sequence of the entire or partial promoter region of RIIAD1 gene to bisulfite treatment, and the promotor region includes a CpG site and a cytosine base not included in CpG sites.
  • the cytosine not included in CpG sites may be any cytosine other than those contained in the CpG sites.
  • the nucleic acid can be obtained by subjecting a nucleic acid isolated from a subject to bisulfite treatment.
  • a non-methylated cytosine in the isolated DNA is converted to uracil by bisulfate treatment of the isolated DNA, while a methylated cytosine is not converted.
  • the information on breast cancer can be obtained by analyzing methylation status of CpG sites in the polynucleotide.
  • the isolated DNA can be obtained in the same manner as that described for preparation of the DNA sample.
  • the bisulfite treatment, the analysis of methylation status and the obtainment of information on breast cancer are also the same as previously described.
  • the size of the nucleic acid used as the marker as envisaged herein is not particularly limited as long as it allows analysis of methylation status by the MSP method, sequencing method or mass spectrometry, but is preferably 50 to 200 bases and more preferably 80 to 130 bases.
  • Examples of the nucleic acid used as the marker as envisaged herein include a nucleic acid having a base sequence SEQ ID NO: 2.
  • the nucleic acid having the base sequence SEQ ID NO: 2 is suitable for analysis of methylation status by the MSP method.
  • kits for detecting breast cancer
  • the kit as envisaged herein includes a primer for amplifying a nucleic acid after bisulfite treatment.
  • a primer for amplifying a nucleic acid after bisulfite treatment.
  • Such a primer is capable of specifically hybridizing to a nucleic acid consisting of a base sequence where cytosine present in a site other than a CpG site is converted to another base in a base sequence having a CpG site in a promotor region of RIIAD1 gene.
  • Such a primer also specifically hybridizes to a region including a methylated CpG site.
  • the primer may be capable of hybridizing specifically with nucleotide sequence comprising both a methylated CpG and a cytosine which is not in a CpG site and converted to another base.
  • the kit may comprise a first primer which hybridizes specifically to a region including a methylated CpG site in a promotor region of RIIAD1 gene.
  • the primer included in the kits envisaged herein may be any primer for analysis of methylation status of CpG sites according to mass spectrometry such as MassARRAY (registered trademark) or an analysis method involving PCR amplification such as the MSP method and the bisulfite sequencing method.
  • the primer is preferably a primer used for mass spectrometry such as Mass ARRAY (registered trademark) or for the MSP method.
  • the base sequence of each primer may be appropriately selected by a person skilled in the art based on the base sequence in the promoter region. Examples of the primer include primers respectively having base sequences SEQ ID NOs: 3 and 4.
  • the kit may include a second primer.
  • the second primer can hybridize to a nucleic acid consisting of a base sequence where cytosine is converted to another base in a base sequence having a CpG site in a promotor region of RIIAD1 gene and hybridize to a region including a sequence in which cytosine in a non-methylated CpG site is converted to another base by converting treatment.
  • the present disclosure also encompasses a computer program product for enabling a computer to provide information on breast cancer in a subject.
  • Examples of the computer program product include a program downloadable from the Internet and a computer readable recording medium storing the program.
  • FIG. 5 is a schematic view of an example of a diagnosis assisting device used for providing information on breast cancer in a subject.
  • a diagnosis assisting device 10 illustrated in Fig. 5 includes a measurement device 20 and a determination device 30 connected to the measurement device 20.
  • the measurement device 20 may be, when methylation status is analyzed by the MSP method, a gel imaging device such as a fluorescence image scanner.
  • a gel imaging device such as a fluorescence image scanner.
  • the measurement device 20 onto which a gel obtained by electrophoresis of a reaction solution after nucleic acid amplification by the MSP method is mounted detects amplification products.
  • the measurement device 20 then obtains information on gel image of the amplification products and sends the obtained information to the determination device 30.
  • the measurement device 20 may be an MALDI-TOF mass spectrometer.
  • the measurement device 20 obtains mass spectrometric information such as the time of flight or the mass-to-charge ratio (m/z value) of a substance to be analyzed.
  • the determination device 30 includes a computer main body 300, an input unit 301 including a keyboard or mouse, and a display unit 302 which is configured by an LCD or CRT and displays information on specimen or analysis result.
  • the determination device 30 obtains information on gel image of the amplification products from the measurement device 20.
  • the determination device 30 executes program to provide information on breast cancer in a subject based on these information.
  • the determination device 30 may be a device different from the measurement device 20, or may be a device that includes the measurement device 20. In the latter case, the determination device 30 may be the diagnosis assisting device 10 in itself.
  • Fig. 6 is a block diagram showing software of the computer main body 300 of the determination device 30 as a functional block.
  • the computer includes an acquisition unit 321, a storage unit 322, a calculating unit 323, a determination unit 324, and an output unit 325.
  • the acquisition unit 321 is communicably connected to the measurement device 20 via a network.
  • the acquisition unit 321 obtains the information provided from the measurement device 20.
  • the storage unit 322 stores a threshold necessary for determination, a formula for obtaining the band intensity, and a processing program.
  • the calculating unit 323 calculates the band intensity according to the stored processing program using the information obtained by the acquisition unit 321.
  • the determination unit 324 determines whether the band intensity which has been obtained by the acquisition unit 321 or calculated by the calculating unit 323 is not less than the threshold stored in the storage unit 322.
  • the output unit 325 outputs the analysis result determined by the determination unit 324 to the display unit 302 as information on breast cancer in a subject (e.g., the presence or absence of breast cancer cells in a biological sample collected from a subject).
  • Fig. 7 is a block diagram showing a hardware configuration of the computer main body 300 shown in Fig. 6 .
  • the computer main body 300 includes a central processing unit (CPU) 310, a read only memory (ROM) 311, a random access memory (RAM) 312, a hard disk 313, an input/output interface 314, a readout device 315, a communication interface 316, and an image output interface 317.
  • the CPU 310, the ROM 311, the RAM 312, the hard disk 313, the input/output interface 314, the readout device 315, the communication interface 316, and the image output interface 317 are data-communicably connected by a bus 318.
  • the CPU 310 can execute the program stored in the ROM 311 and the program loaded on the RAM 312. When the CPU 310 executes the program, each of the functions shown in Fig. 6 is executed. As a result, the determination device 30 functions as the determination device for providing information on breast cancer in a subject.
  • the ROM 311 is configured to include mask ROM, PROM, EPROM, EEPROM, and the like. As described above, the ROM 311 stores program to be executed by the CPU 310 and data used for the program.
  • the RAM 312 is configured to include SRAM and DRAM.
  • the RAM 312 is used to read out the programs recorded on the ROM 311 and the hard disk 313.
  • the RAM 312 is also used as a working area of the CPU 310 when these programs are executed.
  • the hard disk 313 is installed with programs to be executed by the CPU 310, such as operating system and application program (computer program for providing information on breast cancer in a subject) as well as data used in executing the programs.
  • programs to be executed by the CPU 310 such as operating system and application program (computer program for providing information on breast cancer in a subject) as well as data used in executing the programs.
  • the readout device 315 is configured to include a flexible disk drive, a CD-ROM drive, and a DVD-ROM drive.
  • the readout device 315 can read out programs or data recorded on a portable recording medium 40.
  • the input/output interface 314 is configured to include a serial interface such as USB, IEEE 1394 or RS-232C, a parallel interface such as SCSI, IDE or IEEE 1284, and an analog interface including a D/A converter or an A/D converter.
  • the input unit 301 such as a keyboard or mouse is connected to the input/output interface 314. An operator can input various instructions to the computer main body 300 via the input unit 301.
  • the communication interface 316 is, for example, an Ethernet (registered trademark) interface.
  • the computer main body 300 can send printing data to a printer and the like via the communication interface 316.
  • the image output interface 317 is connected to the display unit 302 including LCD, CRT or the like.
  • the display unit 302 can output a video signal according to the image data provided from the CPU 310.
  • the display unit 302 displays the image (screen) according to the input video signal.
  • Fig. 8 is an example of a flow chart for obtaining information on breast cancer.
  • the acquisition unit 321 of the diagnosis assisting device 10 obtains information on gel image of RIIAD1 gene from the measurement device 20.
  • the calculating unit 323 obtains the band intensity from the obtained information on gel image. The calculating unit 323 sends the information to the storage unit 322.
  • step S1-3 the determination unit 324 determines whether the band intensity obtained in step S1-2 is not less than the threshold stored in the storage unit 322.
  • the routine proceeds to step S1-4.
  • the determination unit 324 sends the analysis result showing that breast cancer cells are present in the biological sample from the subject to the output unit 325.
  • the routine proceeds to step S1-5.
  • the determination unit 324 sends the analysis result showing that breast cancer cells are not present in the biological sample from the subject to the output unit 325.
  • step S1-6 the output unit 325 finally outputs the analysis result as the information on breast cancer in a subject.
  • the output unit 325 displays it on the display unit 302. Consequently, the diagnosis assisting device 10 can provide a physician or the like information assisting to judge whether the subject has breast cancer.
  • Example 1 Methylation data on Infinium HumanMethylation450 BeadChip (Illumina, Inc.), which are published in TCGA (The Cancer Genome Atlas: http://tcga-data.nci.nih.gov/tcga/tcgaHome2.jsp), were collected for cancerous tissues (548 specimens) and non-cancerous (mammary) tissues (98 specimens) of breast cancer. Further, methylation data on Infinium HumanMethylation450 BeadChip, which are published in the publication of Nazor K L et al. (Recurrent variations in DNA methylation in human pluripotent stem cells and their differentiated derivatives. Cell Stem Cell 2012; 10(5): 620-634 ), were collected for normal mammary tissues (23 specimens).
  • the promotor region of RIIAD1 gene was identified as a marker which is specifically methylated in cancerous tissues of breast cancer (refer to Fig. 1 ). These markers are also referred to as "present markers" hereinbelow.
  • Example 2 methylation data of 15 types of cancer/tumor tissue specimens, 12 types of non-cancerous tissue specimens, and 19 types of normal tissue specimens were compared. The number of specimens for the respective tissues is shown in the following tables.
  • Cancer/tumor specimens Tissues The number of specimens Brain tumor 114 Lung cancer 370 Breast cancer 548 Gastric cancer 69 Colon cancer 324 Liver cancer 81 Renal cancer 363 Bladder cancer 78 Uterine body cancer 334 Ovarian cancer 49 Prostatic cancer 153 Acute leukemia 192 Sarcoma 73 Malignant melanoma 242 Thyroid cancer 316
  • Table 3 Non-cancerous tissue Tissues The number of specimens Brain tumor 1 Lung cancer 75 Breast cancer 98 Gastric cancer 2 Colon cancer 40 Hepatic cancer 14 Renal cancer 208 Bladder cancer 15 Uterine body cancer 36 Ovarian cancer 1 Prostatic cancer 49 Thyroid cancer 36
  • Normal tissues Tissues RCAST Literature 1 Literature 2 Total Normal brain (Bra
  • the methylation data in this context are the methylation rate (mCpG) of a CpG site in RIIAD1 obtained as follows.
  • the Infinium HumanMethylation450 BeadChip include probes for methylated CpG sites and probes for non-methylated CpG sites of 482,421 CpG sites on human genome.
  • Fig. 2 The results are shown in Fig. 2 .
  • "normal tissues” represent, among the tissues indicated in Table 4, normal tissues excluding 60 specimens of various normal blood cell components, and "normal blood cells” represent the 60 specimens of various normal blood cell components.
  • all the present markers were rarely methylated in non-cancerous tissues, human normal tissues, and human normal blood cells. Further, all the present markers are specifically highly methylated in breast cancer, compared to other types of cancer. Therefore, it is shown that the present markers are suitable for detection of breast cancer.
  • Example 3 as biological samples derived from breast cancer patients, cancerous tissues collected from breast cancer patients (3 specimens) were used. As control samples, normal mammary tissues (3 specimens) were used.
  • Genomic DNA was extracted from the tissue samples with the use of QIAamp DNA Mini Kit (QIAGEN). Genomic DNA of human peripheral blood lymphocytes was used as the control genomic DNA. The genomic DNA from human peripheral blood lymphocytes was amplified with the use of GenomiPhi v2DNA Amplification Kit (GE Healthcare Life Sciences). The obtained amplified product consisted of non-methylated DNA. The amplification product was fragmented with Bioruptor (COSMO BIO Co., Ltd.) to obtain a solution of non-methylated DNA fragments (0% methylated DNA).
  • the respective DNA fragments (500 ng) obtained as described above were subjected to bisulfite treatment with the use of EZ DNA Methylation Kit (Zymo Research), and the treated genomic DNA was dissolved in sterilized distilled water (80 ⁇ l).
  • MSP was carried out using the measurement samples and control samples obtained in the above section (2).
  • the composition of the PCR reagent, primer sets, and reaction conditions for PCR are shown below.
  • the primer sets used for MSP are shown in Table 5. These primer sets allow generation of amplification products when DNA in the amplified target regions is methylated (hereinafter also referred to as "primer set for methylation detection").
  • primer set for accuracy control a primer set that allows determination on whether or not the bisulfite treatment has been appropriately performed (refer to Table 6).
  • SEQ ID NO: 7 The base sequence of region which is analyzed with the primer set for methylation detection in the promoter region of RIIAD1 gene is shown in SEQ ID NO: 7.
  • the base sequence obtained by bisulfite conversion of this region is shown in SEQ ID NO: 2.
  • the number of cycles "X" is 38 for the primer set for methylation detection, and 40 for the primer set for accuracy control.
  • Example 4 tissue samples collected from various cancer patients and normal tissues from various organs were used. Details of each sample are shown in Table 7.
  • T represents tumor tissue
  • N represents normal tissue
  • PBL peripheral blood leukocyte.
  • Derived tissue The number of specimens Donor Notation Colon Cancer 2 Purchased from BioChain Institute, Inc. T1 T2 Normal 3 N1 N2 N3 Brain Cancer 1 The University of Tokyo T Normal 2 Purchased from BioChain Institute, Inc. N1 N2 Lung Cancer 1 Purchased from BioChain Institute, Inc. T Normal 2 The University of Tokyo N1 N2 Liver Cancer 1 Purchased from BioChain Institute, Inc.
  • T Normal 2 The University of Tokyo N1 N2 Kidney Cancer 1 Purchased in BioChain Institute, Inc.
  • T Normal 2 The University of Tokyo N1 N2 Uterine body Cancer 1 The University of Tokyo T Normal 2 N1 N2 Bladder Cancer 1 Purchased from BioChain Institute, Inc.
  • T Normal 1 N Cervix uteri Normal 1 Purchased from BioChain Institute, Inc. Cervix Testis Normal 1 Purchased from BioChain Institute, Inc. Testis Blood cell Normal 1 Purchased from BioChain Institute, Inc. PBL Stomach Cancer 1 Purchased from BioChain Institute, Inc. T Normal 1 N
  • Genomic DNA was extracted from the tissue samples in the same manner as in Example 3. Genomic DNA of human peripheral blood lymphocytes was used as the control genomic DNA. A solution of non-methylated DNA fragments (0% methylated DNA) and a solution of methylated DNA fragments (100% methylated DNA) were prepared from the genomic DNA of human peripheral blood lymphocytes in the same manner as in Example 3.
  • the respective DNA fragments (500 ng) obtained as described above were subjected to bisulfite treatment with the use of EZ DNA Methylation Kit (Zymo Research), and the treated genomic DNA was dissolved in sterilized distilled water (80 ⁇ l).
  • MSP was carried out using the measurement samples and control samples (DNA after bisulfite treatment) obtained in the above section (2).
  • the composition of the PCR reagent, primer sets, and reaction conditions for PCR used for MSP in Example 4 are the same as those in Example 3.

Landscapes

  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Pathology (AREA)
  • Analytical Chemistry (AREA)
  • Zoology (AREA)
  • Genetics & Genomics (AREA)
  • Wood Science & Technology (AREA)
  • Physics & Mathematics (AREA)
  • Biotechnology (AREA)
  • Microbiology (AREA)
  • Molecular Biology (AREA)
  • Hospice & Palliative Care (AREA)
  • Biophysics (AREA)
  • Oncology (AREA)
  • Biochemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)

Claims (9)

  1. Verfahren zur Gewinnung von Informationen über Brustkrebs, umfassend die Schritte:
    Analysieren des Methylierungsstatus einer in einer Promotorregion des RIIAD1-Gens liegenden CpG-Stelle in der aus einer einem Individuum entnommenen biologischen Probe hergestellten DNA-Probe; und
    Gewinnen von Informationen, die das Vorliegen von Brustkrebszellen in der biologischen Probe anzeigen, wenn das Ergebnis im Bestimmungsschritt das Vorliegen einer methylierten CpG-Stelle anzeigt.
  2. Verfahren nach Anspruch 1, wobei im Analyseschritt der Methylierungsstatus von SEQ ID NO: 7 analysiert wird.
  3. Verfahren nach Anspruch 1 oder 2, wobei der Analyseschritt mit wenigstens einem aus der aus Massenspektrometrie und methylierungsspezifischem PCR-Verfahren bestehenden Gruppe ausgewählten Verfahren ausgeführt wird.
  4. Verfahren nach einem der Ansprüche 1 bis 3, wobei es sich bei der biologischen Probe um ein Gewebe, Blut oder Serum handelt.
  5. Verfahren nach einem der Ansprüche 1 bis 4, wobei der Analyseschritt Berechnen der Methylierungshäufigkeit der Promotorregion umfasst und
    der Gewinnungsschritt Vergleichen der Häufigkeit mit einem vorbestimmten Schwellenwert; und Gewinnen von Informationen, die das Vorliegen von Brustkrebszellen in der biologischen Probe anzeigen, wenn die Häufigkeit gleich dem oder höher als der Schwellenwert ist, umfasst.
  6. Verfahren nach einem der Ansprüche 1 bis 5, wobei das Verfahren Herstellen einer DNA-Probe aus der biologischen Probe umfasst.
  7. Verfahren nach Anspruch 6, wobei der Herstellungsschritt Behandeln von DNA in der biologischen Probe mit Bisulfit umfasst.
  8. Verwendung eines Reagentienkits zum Nachweis von Brustkrebs, wobei das Reagentienkit einen Primer umfasst, der an eine Promotorregion des RIIAD1-Gens hybridisiert, wobei die Promotorregion eine durch eine Bisulfitbehandlung aus unmethyliertem Cytosin überführte Uracilbase; und methylierte Cytosinbase umfasst, und wobei der Primer zum Analysieren des Methylierungsstatus einer CpG-Stelle, in der Promotorregion des RIIAD1-Gens in einer DNA-Probe verwendet wird.
  9. Verwendung nach Anspruch 8, wobei der Primer eine Basensequenz SEQ ID NO: 3 oder 4 umfasst.
EP16163068.6A 2015-03-31 2016-03-31 Verfahren zur gewinnung von informationen über brustkrebs und kit zum nachweis von brustkrebs Active EP3075853B1 (de)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
JP2015073577A JP2016192906A (ja) 2015-03-31 2015-03-31 乳がんに関する情報の取得方法、ならびに乳がんに関する情報を取得するためのマーカー及び乳がん検出用キット

Publications (2)

Publication Number Publication Date
EP3075853A1 EP3075853A1 (de) 2016-10-05
EP3075853B1 true EP3075853B1 (de) 2017-12-06

Family

ID=55642330

Family Applications (1)

Application Number Title Priority Date Filing Date
EP16163068.6A Active EP3075853B1 (de) 2015-03-31 2016-03-31 Verfahren zur gewinnung von informationen über brustkrebs und kit zum nachweis von brustkrebs

Country Status (2)

Country Link
EP (1) EP3075853B1 (de)
JP (1) JP2016192906A (de)

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DK2245199T3 (da) * 2008-02-01 2014-02-03 Gen Hospital Corp Anvendelse af mikrovesikler i diagnosticering, prognosticering og behandling af medicinske sygdomme og tilstande
JPWO2010032797A1 (ja) * 2008-09-19 2012-02-16 シスメックス株式会社 乳癌の転移の判定方法及び血清の評価方法
WO2010074924A1 (en) * 2008-12-23 2010-07-01 University Of Utah Research Foundation Identification and regulation of a novel dna demethylase system
WO2011002024A1 (ja) * 2009-06-30 2011-01-06 シスメックス株式会社 生体試料中の上皮性癌由来の細胞の存否を判定するための方法、分子マーカー及びキット
JP6269492B2 (ja) * 2012-09-19 2018-01-31 シスメックス株式会社 肝細胞癌に関する情報の取得方法、ならびに肝細胞癌に関する情報を取得するためのマーカーおよびキット
EP2899275B1 (de) * 2012-09-19 2018-06-27 Sysmex Corporation Verfahren zur gewinnung von informationen über endometriumkarzinom sowie marker und kit zur gewinnung von informationen über endometriumkarzinom
WO2014046197A1 (ja) * 2012-09-19 2014-03-27 シスメックス株式会社 大腸癌に関する情報の取得方法、ならびに大腸癌に関する情報を取得するためのマーカーおよびキット

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
None *

Also Published As

Publication number Publication date
EP3075853A1 (de) 2016-10-05
JP2016192906A (ja) 2016-11-17

Similar Documents

Publication Publication Date Title
EP2816121B1 (de) Verfahren zur Gewinnung von Informationen über hepatozelluläres Karzinom
EP2808397B1 (de) Verfahren zur Gewinnung von Informationen über Darmkrebs und Marker und Kit zur Gewinnung von Informationen über Darmkrebs
EP2899275B1 (de) Verfahren zur gewinnung von informationen über endometriumkarzinom sowie marker und kit zur gewinnung von informationen über endometriumkarzinom
EP2966183B1 (de) Verfahren zur gewinnung von informationen über lungenkrebs und verwendung von marker und bestimmungsvorrichtung zur gewinnung von informationen über lungenkrebs
EP2977467B1 (de) Verfahren, verwendung von marker und bestimmungsvorrichtung zur gewinnung von informationen über eine vielzahl von krebsarten
EP2899274A1 (de) Verfahren zur gewinnung von informationen über hepatozelluläre karzinome sowie marker und kit zur gewinnung von informationen über hepatozelluläre karzinome
EP2899272B1 (de) Verfahren und verwendung zur gewinnung von informationen über kolorektalkrebs
EP2821487B1 (de) Verfahren zur bestimmung des vorhandenseins oder nichtvorhandenseins von krebszellen aus einem hepatozellulären karzinom sowie bestimmungsmarker und kit
EP3075852B1 (de) Verfahren zur erfassung von informationen über gynäkologischen krebs und nachweiskit für gynäkologischen krebs
EP3075853B1 (de) Verfahren zur gewinnung von informationen über brustkrebs und kit zum nachweis von brustkrebs
EP2966182B1 (de) Verfahren zum erhalt von informationen über uterinkörperkrebs und marker und bestimmungsvorrichtung zum erhalt von informationen über den uterinkörperkrebs
JP6269493B2 (ja) 脳腫瘍に関する情報の取得方法、ならびに脳腫瘍に関する情報を取得するためのマーカーおよびキット
EP3075851B1 (de) Verfahren zur informationserfassung über magensaft und kit zum nachweis von magenkrebs
EP3078745B1 (de) Verfahren zur gewinnung von informationen bezüglich eierstockkrebs und eierstockkrebsnachweiskit
JP6636105B2 (ja) 大腸癌に関する情報の取得方法、ならびに大腸癌に関する情報を取得するためのマーカーおよびキット

Legal Events

Date Code Title Description
PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

AK Designated contracting states

Kind code of ref document: A1

Designated state(s): AL AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO PL PT RO RS SE SI SK SM TR

AX Request for extension of the european patent

Extension state: BA ME

17P Request for examination filed

Effective date: 20170321

RBV Designated contracting states (corrected)

Designated state(s): AL AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO PL PT RO RS SE SI SK SM TR

RIC1 Information provided on ipc code assigned before grant

Ipc: C12Q 1/04 20060101ALI20170419BHEP

Ipc: C12N 15/09 20060101AFI20170419BHEP

Ipc: C12Q 1/68 20060101ALI20170419BHEP

GRAP Despatch of communication of intention to grant a patent

Free format text: ORIGINAL CODE: EPIDOSNIGR1

INTG Intention to grant announced

Effective date: 20170628

GRAS Grant fee paid

Free format text: ORIGINAL CODE: EPIDOSNIGR3

GRAA (expected) grant

Free format text: ORIGINAL CODE: 0009210

AK Designated contracting states

Kind code of ref document: B1

Designated state(s): AL AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO PL PT RO RS SE SI SK SM TR

REG Reference to a national code

Ref country code: GB

Ref legal event code: FG4D

REG Reference to a national code

Ref country code: AT

Ref legal event code: REF

Ref document number: 952399

Country of ref document: AT

Kind code of ref document: T

Effective date: 20171215

Ref country code: CH

Ref legal event code: EP

REG Reference to a national code

Ref country code: IE

Ref legal event code: FG4D

REG Reference to a national code

Ref country code: DE

Ref legal event code: R096

Ref document number: 602016000993

Country of ref document: DE

REG Reference to a national code

Ref country code: NL

Ref legal event code: MP

Effective date: 20171206

REG Reference to a national code

Ref country code: LT

Ref legal event code: MG4D

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: ES

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20171206

Ref country code: NO

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20180306

Ref country code: LT

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20171206

Ref country code: SE

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20171206

Ref country code: FI

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20171206

REG Reference to a national code

Ref country code: AT

Ref legal event code: MK05

Ref document number: 952399

Country of ref document: AT

Kind code of ref document: T

Effective date: 20171206

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: BG

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20180306

Ref country code: LV

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20171206

Ref country code: RS

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20171206

Ref country code: GR

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20180307

Ref country code: HR

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20171206

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: NL

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20171206

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: EE

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20171206

Ref country code: SK

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20171206

Ref country code: CZ

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20171206

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: PL

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20171206

Ref country code: SM

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20171206

Ref country code: IT

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20171206

Ref country code: AT

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20171206

Ref country code: RO

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20171206

REG Reference to a national code

Ref country code: DE

Ref legal event code: R097

Ref document number: 602016000993

Country of ref document: DE

PLBE No opposition filed within time limit

Free format text: ORIGINAL CODE: 0009261

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: NO OPPOSITION FILED WITHIN TIME LIMIT

26N No opposition filed

Effective date: 20180907

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: SI

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20171206

Ref country code: MC

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20171206

Ref country code: DK

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20171206

REG Reference to a national code

Ref country code: BE

Ref legal event code: MM

Effective date: 20180331

REG Reference to a national code

Ref country code: IE

Ref legal event code: MM4A

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: LU

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20180331

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: IE

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20180331

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: BE

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20180331

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: FR

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20180331

REG Reference to a national code

Ref country code: CH

Ref legal event code: PL

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: MT

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20180331

Ref country code: CH

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20190331

Ref country code: LI

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20190331

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: TR

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20171206

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: PT

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20171206

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: HU

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT; INVALID AB INITIO

Effective date: 20160331

Ref country code: MK

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20171206

Ref country code: CY

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20171206

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: AL

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20171206

Ref country code: IS

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20180406

GBPC Gb: european patent ceased through non-payment of renewal fee

Effective date: 20200331

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: GB

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20200331

PGFP Annual fee paid to national office [announced via postgrant information from national office to epo]

Ref country code: DE

Payment date: 20240206

Year of fee payment: 9